Notably, while bevacizumab treatment reduced the expression of Cyclin D1, GLUT-1 and MCT-1, TH reverted such effects, thus showing that VEGF-A is not the only TH-target gene in tumor promotion, and that VEGF-A is part of pro-tumorigenic cascade in the TH-dependent tumorigenic action. Here, SLC2A1 is linked to neoplasm.